Is the DLQI appropriate for medical decision-making in psoriasis patients?

Adrienn Katalin Poór, Valentin Brodszky, Márta Péntek, L. Gulácsi, Gábor Ruzsa, Bernadett Hidvégi, Péter Holló, S. Kárpáti, Miklós Sárdy, Fanni Rencz

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Dermatology Life Quality Index (DLQI) is the most commonly applied measure of health-related quality of life (HRQoL) in psoriasis patients. It is among defining criteria of moderate-to-severe psoriasis and present in treatment guidelines. Our objective was to estimate preference-based HRQoL values (i.e., utilities) for hypothetical health states described by the 10 items of the DLQI in psoriasis patients. Moreover, we compare results to findings of a similar study previously conducted among the general public. A cross-sectional survey was carried out among 238 psoriasis patients. Seven hypothetical DLQI-defined health states with total scores of 6, 11, and 16 (3–3 and 1 states, respectively) were evaluated by time trade-off method. The difference in DLQI scores between hypothetical health states was set at 5 points, as it exceeds the minimal clinically important difference (MCID). Utility scores were found to be homogenous across the seven hypothetical health states (range of means for the 6-point states 0.85–0.91, range of means for the 11-point states 0.83–0.85, and mean of 0.84 for the 16-point state). Overall, mean utilities assessed by psoriasis patients were higher for all seven states compared with the general public (mean difference 0.16–0.28; p < 0.001). In 11 out of the 15 comparisons between health states with DLQI scores differing larger than the MCID, there was no statistically significant difference in utility. Thus, in clinical settings, patients with DLQI scores differing more than the MCID may have identical HRQoL. Improving the definition of moderate-to-severe disease and reconsideration of the DLQI in clinical assessment of psoriasis patients are suggested.

Original languageEnglish
Pages (from-to)47-55
Number of pages9
JournalArchives of Dermatological Research
Volume310
Issue number1
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Dermatology
Psoriasis
Quality of Life
Health
Clinical Decision-Making
Cross-Sectional Studies
Guidelines

Keywords

  • Dermatology Life Quality Index
  • Health-related quality of life
  • Medical decision-making
  • Psoriasis
  • Time trade-off
  • Utility

ASJC Scopus subject areas

  • Dermatology

Cite this

Is the DLQI appropriate for medical decision-making in psoriasis patients? / Poór, Adrienn Katalin; Brodszky, Valentin; Péntek, Márta; Gulácsi, L.; Ruzsa, Gábor; Hidvégi, Bernadett; Holló, Péter; Kárpáti, S.; Sárdy, Miklós; Rencz, Fanni.

In: Archives of Dermatological Research, Vol. 310, No. 1, 01.01.2018, p. 47-55.

Research output: Contribution to journalArticle

Poór, AK, Brodszky, V, Péntek, M, Gulácsi, L, Ruzsa, G, Hidvégi, B, Holló, P, Kárpáti, S, Sárdy, M & Rencz, F 2018, 'Is the DLQI appropriate for medical decision-making in psoriasis patients?', Archives of Dermatological Research, vol. 310, no. 1, pp. 47-55. https://doi.org/10.1007/s00403-017-1794-4
Poór, Adrienn Katalin ; Brodszky, Valentin ; Péntek, Márta ; Gulácsi, L. ; Ruzsa, Gábor ; Hidvégi, Bernadett ; Holló, Péter ; Kárpáti, S. ; Sárdy, Miklós ; Rencz, Fanni. / Is the DLQI appropriate for medical decision-making in psoriasis patients?. In: Archives of Dermatological Research. 2018 ; Vol. 310, No. 1. pp. 47-55.
@article{2d692df84efa4aa7b13cda536e53dfb6,
title = "Is the DLQI appropriate for medical decision-making in psoriasis patients?",
abstract = "Dermatology Life Quality Index (DLQI) is the most commonly applied measure of health-related quality of life (HRQoL) in psoriasis patients. It is among defining criteria of moderate-to-severe psoriasis and present in treatment guidelines. Our objective was to estimate preference-based HRQoL values (i.e., utilities) for hypothetical health states described by the 10 items of the DLQI in psoriasis patients. Moreover, we compare results to findings of a similar study previously conducted among the general public. A cross-sectional survey was carried out among 238 psoriasis patients. Seven hypothetical DLQI-defined health states with total scores of 6, 11, and 16 (3–3 and 1 states, respectively) were evaluated by time trade-off method. The difference in DLQI scores between hypothetical health states was set at 5 points, as it exceeds the minimal clinically important difference (MCID). Utility scores were found to be homogenous across the seven hypothetical health states (range of means for the 6-point states 0.85–0.91, range of means for the 11-point states 0.83–0.85, and mean of 0.84 for the 16-point state). Overall, mean utilities assessed by psoriasis patients were higher for all seven states compared with the general public (mean difference 0.16–0.28; p < 0.001). In 11 out of the 15 comparisons between health states with DLQI scores differing larger than the MCID, there was no statistically significant difference in utility. Thus, in clinical settings, patients with DLQI scores differing more than the MCID may have identical HRQoL. Improving the definition of moderate-to-severe disease and reconsideration of the DLQI in clinical assessment of psoriasis patients are suggested.",
keywords = "Dermatology Life Quality Index, Health-related quality of life, Medical decision-making, Psoriasis, Time trade-off, Utility",
author = "Po{\'o}r, {Adrienn Katalin} and Valentin Brodszky and M{\'a}rta P{\'e}ntek and L. Gul{\'a}csi and G{\'a}bor Ruzsa and Bernadett Hidv{\'e}gi and P{\'e}ter Holl{\'o} and S. K{\'a}rp{\'a}ti and Mikl{\'o}s S{\'a}rdy and Fanni Rencz",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s00403-017-1794-4",
language = "English",
volume = "310",
pages = "47--55",
journal = "Archiv für Dermatologische Forschung",
issn = "0340-3696",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Is the DLQI appropriate for medical decision-making in psoriasis patients?

AU - Poór, Adrienn Katalin

AU - Brodszky, Valentin

AU - Péntek, Márta

AU - Gulácsi, L.

AU - Ruzsa, Gábor

AU - Hidvégi, Bernadett

AU - Holló, Péter

AU - Kárpáti, S.

AU - Sárdy, Miklós

AU - Rencz, Fanni

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Dermatology Life Quality Index (DLQI) is the most commonly applied measure of health-related quality of life (HRQoL) in psoriasis patients. It is among defining criteria of moderate-to-severe psoriasis and present in treatment guidelines. Our objective was to estimate preference-based HRQoL values (i.e., utilities) for hypothetical health states described by the 10 items of the DLQI in psoriasis patients. Moreover, we compare results to findings of a similar study previously conducted among the general public. A cross-sectional survey was carried out among 238 psoriasis patients. Seven hypothetical DLQI-defined health states with total scores of 6, 11, and 16 (3–3 and 1 states, respectively) were evaluated by time trade-off method. The difference in DLQI scores between hypothetical health states was set at 5 points, as it exceeds the minimal clinically important difference (MCID). Utility scores were found to be homogenous across the seven hypothetical health states (range of means for the 6-point states 0.85–0.91, range of means for the 11-point states 0.83–0.85, and mean of 0.84 for the 16-point state). Overall, mean utilities assessed by psoriasis patients were higher for all seven states compared with the general public (mean difference 0.16–0.28; p < 0.001). In 11 out of the 15 comparisons between health states with DLQI scores differing larger than the MCID, there was no statistically significant difference in utility. Thus, in clinical settings, patients with DLQI scores differing more than the MCID may have identical HRQoL. Improving the definition of moderate-to-severe disease and reconsideration of the DLQI in clinical assessment of psoriasis patients are suggested.

AB - Dermatology Life Quality Index (DLQI) is the most commonly applied measure of health-related quality of life (HRQoL) in psoriasis patients. It is among defining criteria of moderate-to-severe psoriasis and present in treatment guidelines. Our objective was to estimate preference-based HRQoL values (i.e., utilities) for hypothetical health states described by the 10 items of the DLQI in psoriasis patients. Moreover, we compare results to findings of a similar study previously conducted among the general public. A cross-sectional survey was carried out among 238 psoriasis patients. Seven hypothetical DLQI-defined health states with total scores of 6, 11, and 16 (3–3 and 1 states, respectively) were evaluated by time trade-off method. The difference in DLQI scores between hypothetical health states was set at 5 points, as it exceeds the minimal clinically important difference (MCID). Utility scores were found to be homogenous across the seven hypothetical health states (range of means for the 6-point states 0.85–0.91, range of means for the 11-point states 0.83–0.85, and mean of 0.84 for the 16-point state). Overall, mean utilities assessed by psoriasis patients were higher for all seven states compared with the general public (mean difference 0.16–0.28; p < 0.001). In 11 out of the 15 comparisons between health states with DLQI scores differing larger than the MCID, there was no statistically significant difference in utility. Thus, in clinical settings, patients with DLQI scores differing more than the MCID may have identical HRQoL. Improving the definition of moderate-to-severe disease and reconsideration of the DLQI in clinical assessment of psoriasis patients are suggested.

KW - Dermatology Life Quality Index

KW - Health-related quality of life

KW - Medical decision-making

KW - Psoriasis

KW - Time trade-off

KW - Utility

UR - http://www.scopus.com/inward/record.url?scp=85033435075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033435075&partnerID=8YFLogxK

U2 - 10.1007/s00403-017-1794-4

DO - 10.1007/s00403-017-1794-4

M3 - Article

VL - 310

SP - 47

EP - 55

JO - Archiv für Dermatologische Forschung

JF - Archiv für Dermatologische Forschung

SN - 0340-3696

IS - 1

ER -